Kidney Failure
Conditions
Keywords
Graft Failure, Access Blood Flow Monitoring, Clinical Trial Vascular Access, Fistula Failure, Hemodialysis, Vascular Access
Brief summary
The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.
Interventions
DRUGAggrenox
DRUGPlacebo
Sponsors
The Cleveland Clinic
Boston University
Duke University
University of Iowa
MaineHealth
University of Texas Southwestern Medical Center
University of Alabama at Birmingham
Washington University School of Medicine
Baystate Medical Center
Vanderbilt University
CAMC Health System
Emory University
St. Louis University
Tyler Nephrology Associates
Vascular Surgery Associates LLC
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18-21 depending on state regulations * Life expectancy of at least six months * Chronic renal failure with anticipated start of hemodialysis within six months of enrollment, or current dialysis dependence * A new or planned arteriovenous (AV) graft placed in any location for the purpose of hemodialysis. (Any type of graft material and any configuration of the access is acceptable). * The patient is expected to stay at a participating dialysis facility for at least 6 months. * The patient's physician(s) will allow the patient to participate. * Ability to give informed consent.
Exclusion criteria
* Women must not be pregnant, breastfeeding, or plan to be pregnant during the course of the study. * The presence of ongoing bleeding. * The presence of a known bleeding disorder (e.g., hemophilia or von Willebrand's disease). * Recent bleeding episode requiring transfusion within 12 weeks of entry. * The presence of acute ulcer disease. Acute ulcer disease is defined as a new diagnosis of peptic disease including esophagitis, gastritis, or ulcer or the initiation of treatment with proton pump inhibitors, H2 blockers or therapy for Helicobacter pylori within three months prior to obtaining consent. * Known allergy or adverse reaction to Aggrenox or any of its study components (dipyridamole and aspirin). * Required use of warfarin, dipyridamole, non-steroidal antiinflammatory drugs or other antiplatelet agents other than aspirin. * Current uncontrolled hypertension with systolic blood pressure in excess of 200 mm Hg or diastolic blood pressure in excess of 115 mm Hg. * Baseline platelet count less than 75,000/mm3. * Known advanced liver disease with decompensated cirrhosis, jaundice, ascites or bleeding varices. * Current problem with substance abuse. * Concurrent participation in another medical intervention trial. * Anticipated non-compliance with medical care based on physician judgment. * Patient refusal.
Countries
United States
Outcome results
None listed